Endostar First-line Treatment of Advanced NSCLC

NCT03123445 | Unknown Phase 2 DMC FDA Drug

• 1 other identifier: CLOG1701
• Study Type: interventional
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined GP（gemcitabine+cisplatin） scheme for first-line advanced non small cell lung cancer and maintenance treatment.

Conditions

Non Small Cell Lung Cancer

Keywords

endostar

Outcome Measures

Primary Outcomes (1)

• Progression-free Survival (PFS)

  PFS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknown death , or other anti tumor therapy was used.

  Time Frame: up to month 36

Secondary Outcomes (1)

• ORR

  Time Frame: change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.

Study Arms (2)

Endostar + Gemcitabine and Cisplatin

EXPERIMENTAL

Patients in this group will be given endostar combined with gemcitabine and cisplatine.

Drug: Endostar; Drug: Gemcitabine; Drug: Cisplatin

Gemcitabine and Cisplatin

ACTIVE COMPARATOR

Patients in this group will be given gemcitabine and cisplatine.

Drug: Gemcitabine; Drug: Cisplatin

Interventions

Endostar DRUG

Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total

Also known as: Recombinant Human Endostatin Injection

Endostar + Gemcitabine and Cisplatin

Gemcitabine DRUG

Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total

Endostar + Gemcitabine and Cisplatin; Gemcitabine and Cisplatin

Cisplatin DRUG

Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total

Endostar + Gemcitabine and Cisplatin; Gemcitabine and Cisplatin

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Cytological and histological confirmation（Do not accept single sputum cytology in the diagnosis of patients） in patients diagnosed of lung squamous carcinoma; According to a new IASLC (International Association for the Study of Lung Cance) 2009 lung cancer TNM (tumor node metastasis) stages judged stage IIIB or IV non-small cell lung cancer.
• Must have at least one evaluated lesion,according to the RECIST version 1.1 standard (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at least 20 mm);
• Male or female, age between 18 and 75 years old ;
• ECOG(Eastern Cooperative Oncology Group) PS (performance status ) 0\~1；
• Expected survival period ≥ 3 months or more
• Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet count≥ 100 x 109 / L and hemoglobin ≥9 g/dL;
• Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN); aspartate aminotransferase(AST) and Alanine aminotransferase(ALT) acuities ≤2.5 times of the upper limit of normal (ULN); Alkaline phosphatase ≤5 times of the upper limit of normal(ULN);
• Enough renal function：serum creatinine ≤the limit of normal(ULN) or calculated creatinine clearance≥60 mL/min.
• The electrocardiogram (ecg) basically normal,the body had no to heal wounds
• No previous anti-tumor drug therapy, or only received for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the study start.
• Patients had surgery before,but have more than 4 weeks before the study start, and the patient has recovered;
• Women with completed uterus before intact in the group within 28 days must have a negative pregnancy test results (unless amenorrhea for 24 months). If the pregnancy test from the first time for more than 7 days,the patients need for urine pregnancy test(within 7 days before the first delivery).
• Prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions;
• Sign the informed consent.

You may not qualify if:

• Pregnancy, nursing mothers, or female patients with fertility but no contraception.
• Existing serious acute infection, and can not be controlled; Or with fester sex and chronic infection,or wound in delay;
• Original serious heart disease, including: congestive heart failure, uncontrolled high risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension;
• With uncontrolled nerve, mental illness or mental disorders, compliance is poor, can't cooperate and response to treatment; Uncontrolled primary brain tumors or central nervous system(CNS) metastases illness, with obvious symptoms in cranial hypertension or nerve spirit;
• With a bleeding tendency
• Researchers believe that patients should not participate in this test.

Sponsors & Collaborators

• China Medical University, China: lead
• The First Affiliated Hospital of Dalian Medical University: collaborator
• The Second Affiliated Hospital of Dalian Medical University: collaborator
• Liaoning Cancer Hospital & Institute: collaborator
• Shengjing Hospital: collaborator
• General Hospital of Shenyang Military Region: collaborator

Related Publications (4)

• Wang J, Gu LJ, Fu CX, Cao Z, Chen QY. Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma: A meta-analysis based on Chinese patients. Indian J Cancer. 2014 Mar;51 Suppl 3:e106-9. doi: 10.4103/0019-509X.154099.

  PMID: 25818734 BACKGROUND

• Hu W, Fang J, Nie J, Dai L, Zhang J, Chen X, Ma X, Tian G, Wu D, Han S, Han J, Wang Y, Long J. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore). 2016 Jul;95(28):e4183. doi: 10.1097/MD.0000000000004183.

  PMID: 27428214 BACKGROUND

• Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012 Aug 24;10:170. doi: 10.1186/1477-7819-10-170.

  PMID: 22917490 BACKGROUND

• Zhang FL, Gao EY, Shu RB, Wang H, Zhang Y, Sun P, Li M, Tang W, Jiang BQ, Chen SQ, Cui FB. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Asian Pac J Cancer Prev. 2015;16(15):6765-8. doi: 10.7314/apjcp.2015.16.15.6765.

  PMID: 26434908 RESULT

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

endostar protein; Endostatins; Gemcitabine; Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Angiostatic Proteins; Angiogenic Proteins; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Collagen Type XVIII; Non-Fibrillar Collagens; Collagen; Extracellular Matrix Proteins; Scleroproteins; Biological Factors; Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Study Officials

• liu yunpeng, PhD

  First Hospital of China Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

liu yunpeng, PhD

CONTACT

00862483282312; cmu_trial@163.com

jin bo, PhD

CONTACT

00862483282542; jb_cmu@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China

Study Record Dates

• First Submitted: April 5, 2017
• First Posted: April 21, 2017
• Study Start: April 1, 2017
• Primary Completion: April 1, 2019
• Study Completion: September 1, 2019
• Last Updated: April 21, 2017

Record last verified: 2017-04